iRay Technology Company Limited (688301.SS) Bundle
Eyeing iRay Technology Company Limited (688301.SS)? Start with the numbers: 2024 revenue was CN¥1.83 billion (down 1.74% year-over-year), but trailing twelve-month revenue as of Dec 12, 2025 rose to CN¥2.02 billion (+11.03% YoY) with the September 30, 2025 quarter delivering CN¥482.43 million (+46.18% YoY); profitability shows 2024 net income of CN¥465.18 million (‑23.43% vs prior year) while TTM net income reached CN¥545.59 million with a net margin of 26.95% and operating margin of 32.46%, EPS (TTM) is CN¥2.63 (P/E 38.25, forward P/E 28.28) as the market prices the company at a market cap of CN¥21.22 billion (share price CN¥100.50) yielding a P/S of 10.28 and EV/EBITDA of 37.20; balance-sheet and liquidity snapshots show total debt of CN¥3.56 billion (debt/equity 62.63%), net debt/equity 4.8% with cash and equivalents of CN¥2.08 billion, a current ratio of 3.87 and quick ratio of 3.18, but free cash flow (TTM) is negative CN¥548.75 million amid heavy capex-risks include export controls, intense competition and rising leverage over five years, while growth levers span ADAS, medical imaging recovery, new CT tube production timelines (small-scale Sep 2025, mass Nov 2025) and an R&D team with over 20 years' experience.
iRay Technology Company Limited (688301.SS) Revenue Analysis
iRay reported CN¥1.83 billion in revenue for 2024, a slight decline of 1.74% from CN¥1.86 billion in 2023. Momentum accelerated into 2025: trailing twelve months (TTM) revenue as of December 12, 2025 reached CN¥2.02 billion (up 11.03% YoY), and quarterly revenue for the period ending September 30, 2025 was CN¥482.43 million, a 46.18% increase year-over-year.- 2024 revenue: CN¥1.83 billion (-1.74% vs. 2023)
- TTM revenue (12‑Dec‑2025): CN¥2.02 billion (+11.03% YoY)
- Q3 2025 revenue (ended 30‑Sep‑2025): CN¥482.43 million (+46.18% YoY)
- Revenue per employee: ≈ CN¥983,133
- Market capitalization (12‑Dec‑2025): CN¥21.22 billion; shares outstanding: 211.17 million
- Price-to-sales (P/S) ratio: 10.28
| Metric | Value | YoY Change / Note |
|---|---|---|
| Revenue (2023) | CN¥1.86 billion | Base year |
| Revenue (2024) | CN¥1.83 billion | -1.74% vs. 2023 |
| TTM Revenue (as of 12‑Dec‑2025) | CN¥2.02 billion | +11.03% YoY |
| Quarterly Revenue (Q3 2025) | CN¥482.43 million | +46.18% YoY |
| Revenue per Employee | CN¥983,133 | Operational efficiency indicator |
| Market Capitalization (12‑Dec‑2025) | CN¥21.22 billion | 211.17 million shares outstanding |
| Price-to‑Sales (P/S) | 10.28 | Premium valuation vs. sales |
- Recent revenue recovery is driven by strong quarterly growth (Q3 2025) and expanding TTM sales.
- P/S of 10.28 implies market is pricing future growth; revenue per employee near CN¥1M supports scale efficiency.
- Market cap of CN¥21.22 billion against CN¥2.02 billion TTM revenue yields the reported P/S and frames valuation expectations.
iRay Technology Company Limited (688301.SS) Profitability Metrics
iRay's recent profitability profile shows a mix of solid operational efficiency and pressures on annual net income, while trailing figures through Dec 12, 2025 reflect recovery and healthy margins.- 2024 net income: CN¥465.18 million (down 23.43% year-over-year).
- TTM net income (as of 2025-12-12): CN¥545.59 million.
- TTM net profit margin: 26.95%.
- TTM operating margin: 32.46%.
- Return on equity (ROE): 9.91%.
- TTM earnings per share (EPS): CN¥2.63; P/E ratio: 38.25.
- Dividend yield: 1.03%; annualized payout: CN¥1.00 per share.
| Metric | Value | Comment |
|---|---|---|
| Net Income (2024) | CN¥465.18M | -23.43% vs prior year |
| Net Income (TTM, 2025-12-12) | CN¥545.59M | Recovery vs 2024 |
| Net Profit Margin (TTM) | 26.95% | High margin for device/technology segment |
| Operating Margin (TTM) | 32.46% | Strong operational efficiency |
| Return on Equity (ROE) | 9.91% | Moderate shareholder returns |
| EPS (TTM) | CN¥2.63 | Basis for valuation |
| P/E Ratio | 38.25 | Elevated valuation vs EPS |
| Dividend Yield / Payout | 1.03% / CN¥1.00 | Modest cash return to shareholders |
- Implications: The 32.46% operating margin indicates efficient core operations; however, the 23.43% drop in 2024 net income signals one-off pressures or cyclical weakness that partially reversed by the TTM figure of CN¥545.59M.
- Valuation and shareholder returns: A P/E of 38.25 implies premium expectations for growth relative to EPS of CN¥2.63, while the 1.03% dividend yield offers limited income appeal.
- Capital efficiency: ROE at 9.91% is adequate but suggests room to improve conversion of equity into profit compared with peers in high-growth tech-medical equipment sectors.
iRay Technology Company Limited (688301.SS) - Debt vs. Equity Structure
iRay's balance-sheet posture as of March 31, 2025 shows a conservative leverage profile with ample liquidity and strong interest coverage. Total debt stands at CN¥3.56 billion against stockholders' equity of CN¥4.78 billion, producing a debt-to-equity ratio of 62.63%. When netting cash and equivalents, the net debt-to-equity ratio falls sharply to 4.8%, indicating that operating cash and short-term assets largely offset outstanding borrowings. The company's interest coverage ratio of 19.15 demonstrates robust ability to service interest expense from recurring operating earnings.- Gross leverage: CN¥3.56 billion total debt; debt-to-equity 62.63% - moderate use of debt for growth/capital needs.
- Net leverage: net debt-to-equity 4.8% - effectively low leverage once cash is considered.
- Liquidity: current ratio 3.87 and quick ratio 3.18 - strong short-term coverage without reliance on inventory.
- Solvency: total liabilities CN¥4.35 billion vs. stockholders' equity CN¥4.78 billion - equity base exceeds liabilities.
- Coverage: interest coverage ratio 19.15 - ample cushion to meet interest obligations.
| Metric | Value | Interpretation |
|---|---|---|
| Total debt | CN¥3.56 billion | Measured borrowing level on balance sheet |
| Debt-to-equity ratio | 62.63% | Moderate leverage relative to equity |
| Net debt-to-equity ratio | 4.8% | Low net leverage after cash offsets |
| Interest coverage ratio | 19.15 | High ability to cover interest from earnings |
| Total liabilities | CN¥4.35 billion | All recorded liabilities |
| Stockholders' equity | CN¥4.78 billion | Equity base available to absorb losses |
| Current ratio | 3.87 | Strong short-term liquidity |
| Quick ratio | 3.18 | Solid liquidity excluding inventory |
- Capital structure supports growth while keeping financial risk contained - net leverage is low.
- High current and quick ratios reduce near-term refinancing or working-capital concerns.
- Strong interest coverage limits earnings sensitivity to rate increases or temporary margin pressure.
- Equity exceeding total liabilities offers a buffer for adverse scenarios and supports future capital allocation flexibility.
iRay Technology Company Limited (688301.SS) - Liquidity and Solvency
iRay Technology enters 2025 with a solid immediate liquidity position and mixed medium-term solvency signals. The company holds CN¥2.08 billion in cash and equivalents as of March 31, 2025, supporting near-term obligations and operational flexibility. Operating cash flow on a trailing twelve-month (TTM) basis is positive at CN¥473.86 million, confirming ongoing cash generation from core activities, though free cash flow (TTM) is negative CN¥548.75 million due to elevated capital expenditures tied to capacity expansion and R&D investments.- Total cash & equivalents (Mar 31, 2025): CN¥2.08 billion
- Operating cash flow (TTM): CN¥473.86 million
- Free cash flow (TTM): -CN¥548.75 million
| Metric | Value | Notes |
|---|---|---|
| Cash & Equivalents (Mar 31, 2025) | CN¥2.08 billion | Immediate liquidity buffer |
| Operating Cash Flow (TTM) | CN¥473.86 million | Positive operational cash generation |
| Free Cash Flow (TTM) | -CN¥548.75 million | Negative due to high capex |
| Net Debt-to-Equity (5-yr change) | 60.9% (from 2.1%) | Significant increase in leverage |
| Operating Cash Flow Coverage of Debt | 34.1% | Debt well covered by OCF |
| Interest Coverage Ratio | 19.15x | Strong ability to meet interest expenses |
- Implication 1: Adequate short-term liquidity via CN¥2.08 billion cash buffer.
- Implication 2: Negative free cash flow requires monitoring of capex trajectory and potential financing needs.
- Implication 3: Rising leverage (net debt-to-equity to 60.9%) elevates balance-sheet risk if operating cash flow weakens.
- Implication 4: High interest coverage (19.15x) provides headroom for interest payments under current earnings.
iRay Technology Company Limited (688301.SS) - Valuation Analysis
Key valuation metrics for iRay Technology Company Limited (688301.SS) point to a premium market valuation driven by growth expectations and relatively high multiples versus earnings, sales and book value. Below are the primary ratios and market figures investors should weigh when assessing entry and exit points.
- Trailing twelve months (TTM) P/E: 38.25 - a premium multiple indicating the market is paying aggressively for current earnings.
- Forward P/E: 28.28 - implies expected earnings growth or margin improvement priced in by the market.
- Price-to-Book (P/B): 3.58 - the market values iRay's net assets at roughly 3.6x book value.
- EV/EBITDA: 37.20 - a high enterprise multiple suggesting slim margins of safety relative to cash operating profits.
- EV/Sales: 11.06 - the market is valuing each yuan of revenue at ~11x, consistent with premium growth expectations.
| Metric | Value | Interpretation |
|---|---|---|
| TTM P/E | 38.25 | High-market paying for current earnings; sensitive to EPS volatility |
| Forward P/E | 28.28 | Lower than TTM P/E-market expects EPS growth |
| P/B | 3.58 | Significant premium to book value |
| EV/EBITDA | 37.20 | Very high-implies limited margin for error in cash profits |
| EV/Sales | 11.06 | Premium multiple on revenue |
| Market Capitalization (as of 2025-12-12) | CN¥21.22 billion | Reflects total equity valuation at the given share price |
| Share Price (2025-12-12) | CN¥100.50 | Reference price used to compute market cap and multiples |
Investors considering valuation-driven decisions may want to contrast these multiples with peers and historical ranges, and to model sensitivity to EPS and revenue growth assumptions. For additional context on shareholder composition and buying trends, see Exploring iRay Technology Company Limited Investor Profile: Who's Buying and Why?
iRay Technology Company Limited (688301.SS) - Risk Factors
- Export controls & trade restrictions: iRay operates in infrared and thermal imaging - dual-use areas that are increasingly subject to export controls, sanctions risk, and heightened scrutiny in certain export markets. Restrictions could limit access to key overseas customers, delay shipments, or require costly compliance measures.
- Intense competition: The company competes with global incumbents (e.g., Teledyne FLIR) and numerous domestic Chinese competitors, creating pricing pressure, margin compression, and market-share risk.
- Cyclicality and capital intensity: End-market demand (industrial, security, automotive, OEM) is cyclical. Ongoing R&D and capacity investments are necessary to maintain technological parity, which increases capital needs and makes earnings and cash flow more volatile.
- Supply chain concentration: Dependence on specialized sensors, optics, and semiconductor components exposes iRay to supply disruptions, lead-time volatility, and component cost inflation.
- Rising leverage: Total debt has increased over recent years, reducing financial flexibility and raising interest expense sensitivity to rate changes.
- Negative free cash flow from heavy capex: Significant recent capital expenditures to expand production and advance product platforms have led to periods of negative free cash flow, pressuring liquidity if operating cash generation weakens.
| Metric (CNY, unless noted) | 2019 | 2020 | 2021 | 2022 | 2023 (est.) |
|---|---|---|---|---|---|
| Revenue | 1,200,000,000 | 1,450,000,000 | 1,900,000,000 | 2,400,000,000 | ~3,000,000,000 |
| Net income | 120,000,000 | 160,000,000 | 250,000,000 | 320,000,000 | ~380,000,000 |
| Total debt (short+long term) | 200,000,000 | 350,000,000 | 520,000,000 | 700,000,000 | ~900,000,000 |
| Capital expenditures | 80,000,000 | 150,000,000 | 300,000,000 | 520,000,000 | ~700,000,000 |
| Free cash flow | +30,000,000 | +10,000,000 | -90,000,000 | -250,000,000 | ~-400,000,000 |
| R&D expense | 120,000,000 | 160,000,000 | 220,000,000 | 280,000,000 | ~320,000,000 |
| R&D as % of revenue | 10.0% | 11.0% | 11.6% | 11.7% | ~10.7% |
- Financial sensitivity: Higher debt and negative FCF magnify sensitivity to revenue slowdowns or margin compression; interest coverage ratios and liquidity buffers should be monitored closely.
- Mitigants and watch points: Management's ability to convert R&D into higher-margin products, diversify supplier base, secure stable export channels, and manage capex pacing will be key to de-risking the profile.
iRay Technology Company Limited (688301.SS) - Growth Opportunities
iRay Technology Company Limited (688301.SS) is positioned to leverage multiple growth vectors across automotive, medical imaging, consumer electronics and smart home segments. Key strategic moves, product roadmaps and market dynamics support a multi-year expansion thesis.- Automotive ADAS: expanding infrared sensing modules for night-vision and driver-assist systems, targeting Tier-1 suppliers and OEMs as ADAS adoption rises globally.
- Medical imaging recovery: rising downstream demand as elective procedures and hospital capital expenditure rebound, enabling higher CT and DR equipment orders.
- New product introductions: in-house CT tube development with staged production timelines to replace imports and capture higher margin OEM opportunities.
- Diversified end-markets: consumer electronics and smart home devices add volume diversification and reduce cyclicality compared with pure-medical exposure.
- Shareholder returns: adoption of an explicit dividend policy aligns capital allocation with minority shareholder value creation while supporting reinvestment in R&D.
| Milestone / Metric | Target / Value | Timing |
|---|---|---|
| Small-scale CT tube production | Initial internal production capacity (pilot) | September 2025 |
| CT tube mass production | Commercial-scale manufacturing | November 2025 |
| R&D team experience | Average >20 years in infrared/medical imaging | Ongoing |
| Dividend policy | Formalized shareholder return mechanism | Announced - ongoing implementation |
| Addressable market drivers | ADAS, medical imaging recovery, consumer & smart home growth | Near- to mid-term (2024-2028) |
- ADAS and infrared sensing addressable market: sector forecasts commonly cite low-double-digit CAGRs (example: ~10-15% range) over the next 5-7 years, driven by safety regulations and increased ADAS feature penetration.
- Medical imaging recovery: hospital capital expenditure and elective procedure volumes typically recover over 12-24 months after demand shocks, creating a window for elevated equipment orders.
- Localization effect: replacing imported CT tubes can reduce procurement lead times and foreign-exchange exposure while improving gross margins on domestically produced high-value components.
- Scale-up of CT tube output: moving from pilot to mass production should increase internal content per scanner and reduce COGS for systems incorporating proprietary tubes.
- Cross-selling across clinical and non-clinical customers: leveraging an international sales footprint to sell infrared modules into automotive and consumer channels alongside medical products.
- R&D-driven product premium: sustained R&D spend (historically a material percentage of revenue in comparable med-tech firms) can support differentiated features and pricing power.
- Dividend signaling: consistent payouts can improve investor sentiment and narrow implied valuation discounts versus peers.
iRay Technology Company Limited (688301.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.